Pharmaceutical companies from around the world are setting up research and development hubs in China to take advantage of the reams of data generated by a nation of 1.3 billion people. Global pharmaceutical companies are moving into China to use the large amount of data from the country’s 1.3 billion population unfettered by the US/China trade war, as pharmaceuticals are not involved. Sanofi has opened its first Asian research centre in Chengdu, Pfizer subsidiary Upjohn has opened its head office in Shanghai and Shionogi is developing new drugs in China ahead of the US, Europe and its home market in Japan. The US government has imposed tariffs on Chinese goods worth billions of dollars a year, but it does so at the behest of President Donald Trump, who wants Beijing to stop stealing American intellectual property. The country has also joined an international quality specification organisation for the US, Europe and Japan.
Global pharmaceutical companies are moving into China to use the large amount of data from the country’s 1.3 billion population unfettered by the US/China trade war, as pharmaceuticals are not involved. Sanofi has opened its first Asian research centre in Chengdu, Pfizer subsidiary Upjohn has opened its head office in Shanghai and Shionogi is developing new drugs in China ahead of the US, Europe and its home market in Japan. The US government has imposed tariffs on Chinese goods worth billions of dollars a year, but it does so at the behest of President Donald Trump, who wants Beijing to stop stealing American intellectual property. The country has also joined an international quality specification organisation for the US, Europe and Japan.